Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons-Reference-Cited by-同舟云学术

Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons

Published:2011-07-22 Issue:7 Volume:6 Page:e21954
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bailey Jason A.,Ray Balmiki,Greig Nigel H.,Lahiri Debomoy K.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference65 articles.

1. 2011 Alzheimer's disease facts and figures.;W Thies;Alzheimers Dement,2011

2. Alzheimer disease in the US population: prevalence estimates using the 2000 census.;LE Hebert;Arch Neurol,2003

3. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases.;DK Lahiri;Mol Psychiatry,2009

4. The “LEARn” (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps.;DK Lahiri;Exp Gerontol,2010

5. Physical activity, diet, and risk of Alzheimer disease.;N Scarmeas;JAMA,2009

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interaction of exogenous acetylcholinesterase and butyrylcholinesterase with amyloid-β plaques in human brain tissue;Chemico-Biological Interactions;2024-05

2. Mesenchymal stem cell‐derived rapid drug screening system for Alzheimer's disease for the identification of novel drugs;Drug Development Research;2023-08-11

3. Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer’s disease;Ageing Research Reviews;2023-03

4. Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer’s Disease;Biomedical and Pharmacology Journal;2022-09-29

5. Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives;Journal of Alzheimer's Disease Reports;2022-04-18